Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today

BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up by nearly 5% in price, contrasting quite sharply with the 0.4% decline of the S&P 500 index on the day.

A pair of crushing beats

Those results were published just after market hours on Wednesday, and they showed that the company's revenue reached $747 million for its fourth quarter of 2024. That was a beefy (16%) increase over the same period of the previous year. More impressively, non-GAAP (adjusted) net income nearly doubled, coming in at $180 million ($0.92 per share) against the year-ago profit of $95 million.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Both headline numbers obliterated analyst estimates. Collectively, pundits tracking BioMarin's stock were estimating the company would earn a bit over $711 million and post an adjusted net income of only $0.55.

BioMarin attributed the far better-than-expected gains to rising demand for the company's enzyme therapies throughout the world. It also benefited from large-scale government orders.

Driving forward in '25

Management also proffered guidance for the entirety of 2025. BioMarin believes its total revenue will come in at $3.1 billion to $3.2 billion, and adjusted net income will tally $4.20 to $4.40 per share. The consensus analyst estimates for the two line items are, respectively, $3.1 billion and $4.16.

BioMarin is one of those effective drug producers that have developed a strong product lineup, and is clearly skilled at marketing and selling medications. The company is facing a prosperous 2025, meanwhile, so its future looks good too.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $361,026!*
• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $46,425!*
• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $562,659!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Learn more »

*Stock Advisor returns as of February 3, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy.